Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is ...

St. Charles, Missouri, resident Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now ...

The U.S. Food and Drug Administration had just approved LEQEMBI® (lecanemab-irmb, 100 mg/mL, injection for intravenous use), making it the first traditionally-approved anti-amyloid AD treatment ...

The UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...

In what is seen as an unusual decision, the UK’s National Institute for Health and Care Excellence (NICE) says it will ...

NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.

LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. With an aging population and limited ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...

and Leqembi (lecanemab) for use on the National Health Service (NHS) in England. This is the second time NICE made a decision not to approve these treatments for NHS use. Leqembi, marketed by ...